<p>An <i>ROS1</i>-rearrangned tumor showed strong and diffuse cytoplasmic staining (a) (inset: <i>ROS1</i> FISH with split signals). Other tumors showed cytoplasmic staining with membrane accentuation (b), membranous staining with weaker cytoplasmic intensity (c), or cytoplasmic or paranuclear aggregates (d).</p
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
Biliary tract cancers (BTCs) are a pool of diseases with poor prognosis and there is no orphan drug ...
International audienceThe detection of ROS1 and ALK rearrangements is performed for advanced-stage n...
<p>One area of a <i>ROS1</i>-rearranged tumor shows a solid area with intense immunostaining for ROS...
Clinical data confirmed that patients with ROS1 rearrangement are sensitive to specific inhibitors. ...
ROS1 gene rearrangements are reported in 1–2% of lung adenocarcinomas (ACA) and are associated with ...
<p>(A–D) ROS1 IHC staining using D4D6 antibody. (A) Score 0/negative showing no staining; (B) Score ...
<p>(A) Immunohistochemical staining of ROS1 showing negative immunoreactivity (B) <i>ROS1</i> break-...
Aims. To assess the prevalence of ROS1 rearrangements in a retrospective and prospective diagnostic ...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
<div><p><i>ROS1</i> rearrangement is a predictive biomarker for response to the tyrosine kinase inhi...
<p>(A-D) It shows the light micrograph, revealing adenocarcinoma (HE 200 ×). (E-H) Red probes are hy...
AIMS: To assess the prevalence of ROS1 rearrangements in a retrospective and prospective diagnostic ...
<p>When the tumor shows moderate to strong, or diffuse staining on IHC, FISH is recommend to confirm...
<p>A. 2+ score: weak-to-moderate complete membrane staining in more than 10% of tumor cells (objX40)...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
Biliary tract cancers (BTCs) are a pool of diseases with poor prognosis and there is no orphan drug ...
International audienceThe detection of ROS1 and ALK rearrangements is performed for advanced-stage n...
<p>One area of a <i>ROS1</i>-rearranged tumor shows a solid area with intense immunostaining for ROS...
Clinical data confirmed that patients with ROS1 rearrangement are sensitive to specific inhibitors. ...
ROS1 gene rearrangements are reported in 1–2% of lung adenocarcinomas (ACA) and are associated with ...
<p>(A–D) ROS1 IHC staining using D4D6 antibody. (A) Score 0/negative showing no staining; (B) Score ...
<p>(A) Immunohistochemical staining of ROS1 showing negative immunoreactivity (B) <i>ROS1</i> break-...
Aims. To assess the prevalence of ROS1 rearrangements in a retrospective and prospective diagnostic ...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
<div><p><i>ROS1</i> rearrangement is a predictive biomarker for response to the tyrosine kinase inhi...
<p>(A-D) It shows the light micrograph, revealing adenocarcinoma (HE 200 ×). (E-H) Red probes are hy...
AIMS: To assess the prevalence of ROS1 rearrangements in a retrospective and prospective diagnostic ...
<p>When the tumor shows moderate to strong, or diffuse staining on IHC, FISH is recommend to confirm...
<p>A. 2+ score: weak-to-moderate complete membrane staining in more than 10% of tumor cells (objX40)...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
Biliary tract cancers (BTCs) are a pool of diseases with poor prognosis and there is no orphan drug ...
International audienceThe detection of ROS1 and ALK rearrangements is performed for advanced-stage n...